STABILISED VACCINE COMPOSITION

A component for a HIV vaccine comprising: a) an immunogenic fusion protein comprising Nef or an immunogenic fragment or derivative thereof, and p17 Gag and/or p24 Gag or immunogenic fragments or derivatives thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or i...

Full description

Saved in:
Bibliographic Details
Main Authors LEMOINE DOMINIQUE INGRID, PONSARD SOPHIE VALERIE ANNE
Format Patent
LanguageEnglish
Published 10.07.2014
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:A component for a HIV vaccine comprising: a) an immunogenic fusion protein comprising Nef or an immunogenic fragment or derivative thereof, and p17 Gag and/or p24 Gag or immunogenic fragments or derivatives thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them, and b) a stabilising agent selected from the group comprising or consisting of monothioglycerol, cysteine, N-acetyl cysteine or mixtures thereof. The invention also extends to HIV vaccines comprising the same and use in treatment/prevention of HIV.
Bibliography:Application Number: US201314086038